In today’s post, we summarize and quote the main studies that exist on the use of reishi (Ganoderma lucidum) and its active substances in different lung cancers.
LZ-8 protein present in Ganoderma lucidum prevents the proliferation of lung cancer cells (Lewis lung carcinoma) in an in vivo mouse model (1). Researchers conclude that recombinant LZ-8 suppressed tumor metastasis and increased survival rate in animals with Lewis carcinoma.
A study carried out with lung cancer patients’ plasma indicates that Ganoderma lucidum polysaccharides can reverse the effects of immune suppression caused by this cancer (2). Wang et al., 2015, highlighted the efficacy of Ganoderma lucidum beta-glucans to diminish the immune suppression caused in the tumor microenvironment. (3). Researchers suggest the use of these polysaccharides in cancer therapy.
Small multiresistant lung cancer cells respond similarly to cytotoxic Ganoderma species (such as Ganoderma lucidum) extracts than to etoposide and doxorubicin medicines (4). Authors comment that these extracts of the fungus can also reverse the resistance of cells to chemotherapeutic agents.
Ganoderma lucidum polysaccharide-peptides inhibit growth of vascular bundles that nourish tumors in a dose-dependent manner (5). Authors consider that they could be candidates as antiangiogenic agents. This could postpone the time until metastasis and reduce the tumor growth over time.
Ganoderic acid T, present in Ganoderma lucidum carpophores and mycelium, induces death of metastatic cancer cells (95-D cell line) through mitochondrial dysfunction. It also increases production of the tumor suppressor protein p53 (6). The author concludes that it could be used as a chemotherapeutic agent.
Clinical studies have shown that G. lucidum polysaccharides improve immune functions [eg, NK cell activity] in patients with advanced solid tumors (7).
Ganoderma lucidum reduce the incidence of lung tumors (pulmonary adenoma) produced in mice by benzopyrene injection (8). It could be considered a chemoprotective agent.
1. Lin TY, Hsu HY. Ling Zhi-8 reduces lung cancer mobility and metastasis through disruption of focal adhesion and induction of MDM2-mediated Slug degradation. Cancer Lett. 2016;375(2):340-8.
2. Sun LX, Li WD, Lin ZB, Duan XS, Li XF, Yang N, et al. Protection against lung cancer patient plasma-induced lymphocyte suppression by Ganoderma lucidum polysaccharides. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2014;33(2):289-99.
3. Wang WJ, Wu YS, Chen S, Liu CF, Chen SN. Mushroom beta-Glucan May Immunomodulate the Tumor-Associated Macrophages in the Lewis Lung Carcinoma. BioMed research international. 2015;2015:604385.
4. Sadava D, Still DW, Mudry RR, Kane SE. Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Letters. 2009;277(2):182-9.
5. Cao QZ, Lin ZB. Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sciences. 2006;78(13):1457-63.
6. Tang W, Liu JW, Zhao WM, Wei DZ, Zhong JJ. Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci. 2006;80(3):205-11.
7. Gao Y, Tang W, Dai X, Gao H, Chen G, Ye J, et al. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food. 2005;8(2):159-68.
8. Yun TK, Kim SH, Lee YS. Trial of a new medium-term model using Benzo(a)pyrene induced lung tumor in newborn mice. Anticancer Research. 1995;15(3):839-45.